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Abstract
Background: The efficacy of the CTL component of a future HIV-1 vaccine will depend on the induction of
responses with the most potent antiviral activity and broad HLA class I restriction. However, current HIV vaccine
designs are largely based on viral sequence alignments only, not incorporating experimental data on T cell
function and specificity.
Methods: Here, 950 untreated HIV-1 clade B or -C infected individuals were tested for responses to sets of 410
overlapping peptides (OLP) spanning the entire HIV-1 proteome. For each OLP, a “protective ratio” (PR) was
calculated as the ratio of median viral loads (VL) between OLP non-responders and responders.
Results: For both clades, there was a negative relationship between the PR and the entropy of the OLP sequence.
There was also a significant additive effect of multiple responses to beneficial OLP. Responses to beneficial OLP
were of significantly higher functional avidity than responses to non-beneficial OLP. They also had superior in-vitro
antiviral activities and, importantly, were at least as predictive of individuals’ viral loads than their HLA class I
genotypes.
Conclusions: The data thus identify immunogen sequence candidates for HIV and provide an approach for T cell
immunogen design applicable to other viral infections.
Keywords: HIV specific CTL, clade B, clade C, HLA, vaccine immunogen design, functional avidity, epitope, entropy,
immune correlate
Background
HIV-1 infection induces strong and broadly directed
HLA class I restricted T cell responses for which speci-
fic epitopes and restricting HLA class I alleles have been
associated with relative in vivo viral control [1]. The
bulk of the anti-viral CTL response appears to be dis-
proportionately HLA-B restricted, but the relative con-
tribution of targeted viral regions and restricting HLA
molecules on the effectiveness of these responses
remains unclear [2-5]. In addition, the impact of HIV-1
sequence diversity on the effectiveness of virus-specific
T cell immunity in vivo is unclear, as functional con-
straints of escape variants, codon-usage at individual
protein positions, T cell receptor (TCR) plasticity and
functional avidity and cross-reactivity potential may all
contribute to the overall antiviral activity of a specific T
cell response [6-13]. Of note, T cell responses to Gag
have most consistently been associated with reduced
viral loads in both clade B and clade C infected cohorts
[14-16]; however, the specific regions in Gag responsible
for this effective control remain poorly defined. In addi-
tion, it is unclear whether the relative benefit of Gag is
due to any other specific characteristic of this protein,
such as rapid antigen-representation upon infection,
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or inherently greater processability and immunogenicity,
particularly in the context of selected HLA class I alleles
[17,18]. Thus, concerns remain that a purely Gag-based
vaccine might mainly benefit those people with a parti-
cular HLA genotype and will not take advantage of
potentially beneficial targets outside of Gag [4,16,17,19].
In addition, CTL escape and viral fitness studies have
focused largely on Gag-derived epitopes presented in
the context of protective HLA class I alleles such as
HLA-B27 and -B57 [7,20,21], yielding results that may
not be generalizable to the genetically diverse majority
of the human population. Furthermore, many studies
have focused on immunodominant targets only, despite
some studies in HIV-1 and SIV infection demonstrating
a crucial contribution of sub-dominant responses to tar-
gets outside of Gag to the effective in-vivo viral control
[4,22]. Thus, the current view on what may constitute a
protective cellular immune response to HIV-1 is likely
biased towards a immunodominant responses and those
restricted by frequent HLA class I alleles and HLA
alleles associated with superior disease outcome.
To overcome these potential limitations, the design of
an effective and broadly applicable HIV-1 vaccine
should to be based on information gained through com-
prehensive analyses that extend across large portions of
the population’s HLA class I heterogeneity. Here we
focus on three cohorts totaling more than 950
untreated, chronically HIV-1 infected individuals with
clade B and C infections, from which responses to cer-
tain regions of the viral genome and specific T cell
response patterns emerge as correlates of viral control.
Importantly, the analyses identify functional properties
unique to these responses and control for the impact of
HLA class I alleles known to be associated with superior
control of HIV-1 infection, thus providing vaccine
immunogen sequence candidates with potential useful-
ness in a broadly applicable HIV-1 vaccine.
Methods
Cohorts
A HIV clade B infected cohort of 223 chronically
infected, treatment naïve individuals was recruited and
tested at IMPACTA in Lima, Peru. The majority (78%)
of enrollees were male and all recruited individuals con-
sidered themselves to be of a mixed Amerindian ethni-
city [14]. The cohort had a median viral load 37,237
copies/ml (range < 50- > 750,000) and a median CD4
count of 385 cell/ul (range170-1151). A second clade B
infected cohort was established at the HIV-1 outpatient
clinic “Lluita contra la SIDA” at Hospital Germans Trias
i Pujol in Badalona (Barcelona, Spain) consisting of 48
treatment-naïve subjects with viral loads below 10,000
and CD4 cell counts > 350 cells/mm
3 ("controllers”,n=
24) or above 50,000 copies/ m la n dC D 4c e l lc o u n t s<
350 cells/mm
3 ("non-controllers”,n=2 4 ) .T h eH I V - 1
clade C infected cohort has been described in the past
and consisted of 631 treatment naïve South African with
a median viral load of 37,900 copies/ml (range < 50->
750,000) and a median CD4 count of 393 cells/ul (range
1-1378) [16]. An additional 78 from a recently published
cohort in Boston were included in the analyses of func-
tional avidities [23-29]. HLA typing was performed as
previously described using SSP-PCR [30]. For Hepitope
and FASS analyses, 4digit typing was used for the Lima
cohort and 2-digit typing for the Durban cohort. Proto-
cols were approved in Lima by the IMPACTA Human
Research Committee, in Durban by the Ethical Commit-
tee of the Nelson R. Mandela School of Medicine at the
University of KwaZulu-Natal and in Barcelona by the
Human Research Committee at Hospital Germans Trias
i Pujol. All subjects provided written informed consent.
Peptide test set and ELISpot assay: Previously
described peptide sets matching HLA-clade B and C
consensus sequences were used in all experiments for
which the OLP-specific entropies have been calculated
in the past, based on available sequence datasets [31-33]
and http://www.hiv.lanl.gov/content/immunology/hla-
tem/index.html. The peptides were clade-specific sets of
adapted 18mers, overlapping by 11 residues designed
using the PeptGen tool available at the Los Alamos HIV
database http://www.hiv.lanl.gov/content/sequence/
PEPTGEN/peptgen.html. The individual OLP in the
peptide sets for clade B and clade C had all the same
starting and ending position relative to the source pro-
tein and follow the same numbering across the entire
viral proteome for both clades. Peripheral blood mono-
nuclear cells (PBMCs) were separated from whole blood
by density centrifugation and used directly to test for
CD8
+ T cell responses in vitro. IFN-g ELISpot assays
were performed as described previously, using Mabtech
antibodies (Mabtech, Stockholm, Sweden) and a matrix
format that allowed simultaneous testing of all 410 over-
lapping (OLP) peptides in the respective test set [14].
Thresholds for positive responses were defined as:
exceeding 5 spots (50 SFC/10
6) per well and exceeding
the mean of negative wells plus 3 standard deviation or
three times the mean of negative wells, whichever was
higher. Stimulation with PHA was used as a positive
control in all ELISpot assays.
Definition of functional avidity
Responses targeting 18 mer OLP in HIV-1 Gag p24
were assessed for their functional avidity using OLP-spe-
cific sets of 10 mer peptides overlapping by 9 residues
that span the 18 mer peptide sequence. Functional avid-
ity was defined as the peptide concentration needed to
elicit half maximal response rates in the ELISpot assay
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fit using GraphPad Prism software [13].
In vitro viral replication inhibition assay
A double mutant virus containing a Nef M20A and
Integrase G140S/Q148H Raltegravir (integrase inhibitor)
resistance mutations was tested for replication in CD4 T
cells in the presence or absence of autologous T cell
lines targeting protective or non-protective OLP. Use of
the Raltegravir-resistant virus allows to prevent potential
replication of autologous virus in the inhibition assays
[28], excludes potential negative impacts on antigen pro-
cessing or CTL functions attributed to protease inhibi-
tors [34] and avoids overlap between the resistance
mutations sites (i.e. G140S/Q148H) and location of ben-
eficial and non-beneficial OLP sequences. In brief, the
p83-10 plasmid containing mutations for a methionine
to alanine substitution at position 20 of the Nef protein
and the p83-2 plasmid engineered to contain the G140S
and Q148H mutations in the integrase were combined
to produce a virus that is replication competent, highly
resistant to Raltegravir and does not downregulate HLA
class I in infected cells [35,36]. Although not entirely
physiological, this approach was chosen to potentially
increase the signal in the in vitro inhibition assay, even
when responses were restricted by Nef-sensitive HLA
class I alleles. Plasmids were co-transfected into MT4
cells and virus was harvested after 7 days [35,37,38].
Autologous CD4 cells were enriched by magnetic beads
isolation (Miltenyi) and expanded for 3 days using a bi-
specific anti-CD3/8 antibody and IL-2 containing med-
ium (50 IU r-IL2) before infecting them at multiplicities
of infection (MOI) between 0.01 and 1. Effector cells
were obtained by stimulating PBMC with either benefi-
cial or non-beneficial OLP for 12 days before isolating
specific OLP-reactive cells by IFN-g capture assay
according to manufacturers’ instructions (Miltenyi, Ber-
gisch Gladbach, Germany). The effector T cells were
analyzed by flow cytometry for the specificity to their
respective targets after capture assay and quantified to
adjust effector-to-target ratios. Since the NL4-3 back-
bone sequence differed in several positions in beneficial
and non-beneficial OLP, the epitope specificity was pre-
dicted based on the HLA class I genotype of the tested
individual and responses confirmed to efficiently recog-
nize variant sequences in the NL4-3 backbone sequence.
Culture supernatant was harvested and replaced by Ral-
tegravir containing medium 0.05 μg/ml after 72 h.
Levels of Gagp24 in the culture supernatant were deter-
mined by ELISA as described [39].
Statistical Analyses
Statistical analyses were performed using Prism Version
5 and R Statistical Language [40]. Results are presented
as median values unless otherwise stated. Tests included
ANOVA, non-parametric Mann-Whitney test (two-
tailed) and Spearman rank test. The significance of dif-
ferences in viral load distribution between OLP-respon-
ders and OLP-non-responders was assessed by a two-
sided Student’s T Test with multiple tests addressed
using, instead of a Bonferroni correction, a q-value
approach to compensate for multiple comparisons [39].
T h em u l t i v a r i a t ea n a l y s i sw a sb a s e do nan o v e lm u l t i -
variate combined regression method known as FASS, a
forward selection method combined with all-subsets
regression [41-43]. Briefly, the FASS approach works by
iteratively performing the following procedure: Let ‘V’
be the set of all variables and ‘M’ be the set of variables
included in a model. In the first step, those variables
that are not already in the model are divided into equal-
sized blocks of variables (the last block may have less
than ‘g’ variables). Then, for each block of variables, ‘m’
is a new estimated and evaluated model using the Baye-
sian Information Criterion (BIC). The best model ‘m’
according to its BIC is retained and the procedure starts
all over again until in one step or more the model is not
improved.
Results
HIV-1-specific T cell responses targeting conserved
regions are associated with lower viral loads
In a first analysis, HIV-1-specific T cell responses were
assessed in a cohort of 223 HIV-1 clade B infected indi-
viduals recruited in Lima, Peru using IFNg ELISpot
assays and a previously described set of 410 clade B
overlapping peptides (OLP) [14,31]. For each OLP, a
protective ratio (PR) was calculated as the ratio of the
median viral loads between OLP non-responders and
OLP responders, such that OLP with PR > 1 were
reflective of OLP predominantly targeted by individuals
with reduced viral loads. OLP-specific PR were a) com-
pared between OLP spanning the different viral proteins
and b) correlated with the viral sequence heterogeneity
in the region covered by the OLP. The data showed
highest median PR values for OLP spanning the Gag
protein sequence, whereas Nef, Env and Tat had the
lowest median PR values (Figure 1A, p < 0.0001,
ANOVA). A protein-subunit-breakdown of PR values
showed the p15 subunit of Gag and RT in Pol to score
less favorable than the remainder of the respective pro-
teins (Figure 1B, p = 0.0032 and p = 0.0025, respec-
tively). While these data confirm the association
between HIV-1 Gag-specific responses and lower viral
loads, it is important to note that all proteins contained
OLP with PR > 1, suggesting that some beneficial
responses can be located outside of Gag; data that has
not emerged from any of the previous studies linking
Gag responses to relative viral control. At the same
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Figure 1 Localization and conservation of beneficial and non-beneficial OLP in HIV-1 clade B and C cohorts. Total HIV-1-specific T cell
responses were assessed in a cohort of 223 chronically HIV clade B infected, untreated individuals in Lima, Peru (graphs A-C) and in 631
chronically HIV clade C infected, untreated individuals in Durban, South Africa (graphs D-F) using peptide test sets of 410 18 mer overlapping
peptides (OLP) spanning the consensus B and C sequences, respectively [2,31]. For each OLP, the protective ratio (PR, defined as “the ratio of the
log median viral load in OLP non-responders divided by log median viral load in OLP responders”) was determined. Each symbol represents an
individual OLP, grouped either by (A, D) proteins or (B, E) protein-subunits for OLP located in Gag, Pol and Env (p-values in A, D based on
ANOVA, in B, E on Mann-Whitney by pariwise comparing the different protein subunits, red lines indicating median PR values). In (C and F), the
OLP-specific entropy (a measure of the viral diversity in the region the OLP spans) is compared to the OLP-specific PR and shows an inverse
association between the sequence conservation and PR (Spearman rank).
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Page 4 of 20time, all proteins contained OLP with PR < 1, indicating
that proteins considered overall beneficial may contain
non-beneficial regions as well. In addition, when the
OLP-specific PR was compared to the sequence entropy
of the region spanned by the individual OLP, a signifi-
cant negative correlation between PR and entropy was
observed (p = 0.0028, r = -0.15; Figure 1C). Although
rarely targeted OLP may have introduced statistically
less robust data points in this comparison and caused a
wide scatter of data points, the results show a relative
absence of OLP with high entropy and high PR values,
suggesting that responses to more variable regions are
less effective in mediating in vivo viral control.
To assess whether the above observations would also
hold true outside of clade B infection, the same analyses
were conducted in a cohort of 631 clade C HIV-1
infected subjects enrolled in Durban, South Africa and
tested for responses against a clade C consensus OLP
sequence as described previously [33]. As in clade B
infection, the OLP specific PR values were highest for
OLP spanning Gag without any significant differences
between the Gag and Pol protein subunits (Figure 1D
and 1E). As in the clade B cohort, the PR values were
negatively correlated with the OLP-specific entropy (p =
0.0323, Figure 1F), confirming the findings in the clade
B cohort and further pointing towards the importance
of targeting conserved segments of the viral proteome
for effective in vivo viral control.
Identification of individual beneficial OLP sequences in
clade B and C infection
In order to identify individual OLP that were signifi-
cantly more frequently targeted in individuals with rela-
tive viral control and to compare the beneficial OLP in
clade B and C infection, the viral load distribution in
OLP-responders and non-responders was analyzed indi-
vidually for each OLP. For the clade B cohort in Peru,
the analyses yielded 43 OLP sequences for which the
median viral load differed between the two groups with
an uncorrected p-value of < 0.05. Of these 43 OLP, 26
w e r eO L Pw i t haP R>1( r e f e r r e dt oa s“beneficial”
OLP), and 17 OLP with a PR < 1 ("non-beneficial” OLP,
Table 1). The distribution of OLP with PR > 1 among
viral proteins was biased towards Gag and Pol, while
Env produced exclusively OLP with PR < 1 (Figure 2A).
The same analyses were repeated for the clade C cohort
in Durban, which due to its larger size allowed to apply
more stringent statistical criteria to identify beneficial
and non-beneficial OLP. To compensate for multiple sta-
tistical comparisons, we employed a previously described
false-discovery rate approach [39], resulting in the identi-
fication of 33 clade C OLP with q-values of < 0.2 (i.e.
OLP with significantly different viral load distributions
between OLP-responders and non-responders with a
false positive discovery rate (q-value) of 20%). The 33
OLP identified were comprised of 22 beneficial OLP and
11 non-beneficial OLP, with the beneficial OLP being
again located in Gag, Pol and Vif, similar to what was
seen in the clade B cohort (Figure 2B).
In both cohorts, the total breadth and magnitude of
responses did not correlate with viral loads as reported
for parts of these cohorts in the past [14,16]. The OLP
with significant differences in median viral loads (43
OLP in clade B and 33 OLP in clade C, Tables 1 and 2,
respectively, i.e. “scoring OLP”), were more often tar-
geted in their respective cohort than OLP that did not
score with a significant difference in viral loads (p =
0.0015 Lima; p < 0.0001 Durban). However, beneficial
and non-beneficial OLP were equally frequently targeted
in either cohort. Also, there was no difference in the
median magnitude of the OLP-specific responses,
regardless whether it was a beneficial, non-beneficial or
not-scoring OLP (all p > 0.7, data not shown). Finally,
there was no correlation between the number of total
OLP responses (against all 410 OLP) and the magnitude
of responses to beneficial OLP in either cohort, indicat-
ing that the strength of beneficial OLP responses was
not diminished by other responses to the rest of the
viral proteome.
In the clade B cohort, the 26 beneficial and 17 non-
beneficial OLP showed a significant difference in their
median entropy (p = 0.0327, Figure 2C), in line with the
overall negative association between higher PR and
lower sequence entropy seen in the comprehensive
screening including the entire 410 OLP set (Figure 1C).
While this comparison was not significant in clade C
infection, a detailed look at Gag showed that beneficial
Gag clade C OLP had a lower entropy values than the
rest of the Gag OLP, suggesting that targeting of the
most conserved regions even in Gag provided particular
benefits for viral control (Figure 2D, p = 0.0172). These
beneficial OLP were also more frequently targeted
(median of 36 responders) compared to the rest of Gag
OLP (median 12 responders, p = 0.0099), likely reflect-
ing the high epitope density in these regions [33,44].
Finally, the two cohorts showed a partial overlap in
the targeted beneficial and non-beneficial OLP, despite
the vastly different HLA genetics in these two popula-
tions [4,31,45,46]. As Gag was enriched in beneficial
OLP scattered throughout the entire protein sequence,
we used the available reverse transcriptase (RT) protein
structure to assess whether beneficial responses were
targeting structurally related regions of the protein, even
though the linear position of beneficial OLP did not
precisely match between the two clades. Indeed, super-
imposing the locations of beneficial OLP in the RT pro-
tein indicates that in both clades, beneficial OLP fell in
structurally related domains of the RT protein (Figure
Mothe et al. Journal of Translational Medicine 2011, 9:208
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Page 5 of 20Table 1 Beneficial and non-beneficial OLP identified in Lima clade B cohort (p < 0.05)
OLP # Protein Sub-unit OLP clade B
consensus
sequence
Median viral
load in OLP
responders
Median viral
load in OLP
non-responders
Protective Ratio
(PR)*
p-value
3 Gag p17 EKIRLRPGGKKKYKLKHI 22947 39014 1.053 0.037
6 Gag p17 ASRELERFAVNPGLL 15380 43189 1.107 0.001
7 Gag p17 ERFAVNPGLLETSEGCR 25939 38974 1.040 0.049
10 Gag p17 QLQPSLQTGSEELRSLY 16285 37237 1.085 0.031
12 Gag p17 SLYNTVATLYCVHQRIEV 23855 37113 1.044 0.037
23 Gag p24 AFSPEVIPMFSALSEGA 22947 37113 1.048 0.036
31 Gag p24 IAPGQMREPRGSDIA 3563 35483 1.281 0.028
34 Gag p24 STLQEQIGWMTNNPPIPV 6127 37360 1.207 0.002
48 Gag p24 ACQGVGGPGHKARVLAEA 12975 35755 1.107 0.041
60 Gag p15 GKIWPSHKGRPGNFLQSR 16266 36434 1.083 0.044
75 Nef - WLEAQEEEEVGFPVRPQV 13407 37360 1.108 0.026
76 Nef - EVGFPVRPQVPLRPMTYK 59618 29855 0.937 0.001
84 Nef - NYTPGPGIRYPLTFGWCF 55402 30538 0.945 0.006
85 Nef - RYPLTFGWCFKLVPV 69890 29903 0.924 0.002
90 Nef - SLHGMDDPEKEVLVWKF 89687 32650 0.911 0.042
159 Pol Pro KMIGGIGGFIKVRQYDQI 14736 36434 1.094 0.020
160 Pol Pro FIKVRQYDQILIEICGHK 3682 35755 1.277 0.031
161 Pol Pro QILIEICGHKAIGTVLV 9117 35483 1.149 0.050
163 Pol Pro LVGPTPVNIIGRNLLTQI 25965 45637 1.055 0.007
171 Pol RT LVEICTEMEKEGKISKI 1865 35483 1.391 0.014
181 Pol RT LDVGDAYFSVPLDKDFRK 65858 32871 0.937 0.041
195 Pol RT LRWGFTTPDKKHQKEPPF 5624 37113 1.219 0.006
196 Pol RT DKKHQKEPPFLWMGYELH 10103 35483 1.136 0.044
210 Pol RT EIQKQGQGQWTYQIY 18155 35483 1.068 0.045
222 Pol RT PPLVKLWYQLEKEPIVGA 412599 34640 0.808 0.030
230 Pol RT IHLALQDSGLEVNIV 85102 34117 0.919 0.030
237 Pol RT VYLAWVPAHKGIGGNEQV 85102 34117 0.919 0.029
240 Pol RT SAGIRKVLFLDGIDKA 116902 32761 0.891 0.019
269 Pol Int TKELQKQITKIQNFRVYY 6629 35755 1.192 0.030
270 Pol Int TKIQNFRVYYRDSRDPLW 18171 37360 1.073 0.019
271 Pol Int YYRDSRDPLWKGPAKLLW 25939 35755 1.032 0.043
276 Pol Int KIIRDYGKQMAGDDCVA 6629 35755 1.192 0.021
279 Vpr - GPQREPYNEWTLELLEEL 60222 32650 0.944 0.042
307 Env Gp120 DLNNNTNTTSSSGEKMEK 179419 34117 0.863 0.044
311 Env Gp120 IRDKVQKEYALFYKLDVV 179419 32871 0.860 0.008
314 Env Gp120 YRLISCNTSVITQACPKV 58206 31273 0.943 0.008
315 Env Gp120 SVITQACPKVSFEPIPIH 61011 32871 0.944 0.034
320 Env Gp120 TNVSTVQCTHGIRPVV 341587 34640 0.820 0.034
355 Env Gp120 VAPTKAKRRVVQREKRAV 161602 34117 0.870 0.042
399 Env Gp41 VIEVVQRACRAILHIPRR 388089 34640 0.812 0.026
405 Vif - VKHHMYISGKAKGWFYRH 16458 37237 1.084 0.021
406 Vif - GKAKGWFYRHHYESTHPR 16458 37237 1.084 0.022
424 Vif - TKLTEDRWNKPQKTKGHR 10319 36434 1.137 0.014
* PR values in bold indicate PR > 1, i.e. OLP-responses seen more frequently in individuals with reduced viral loads
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Figure 2 Genome distribution, entropy and RT localization of OLP with significant impact on viral loads in HIV-1 clade B and C
infection: The distribution of OLP with significantly elevated or reduced PR across the viral proteome is shown in A) for clade B infection (cut-
off uncorrected p-value of p < 0.05) and in B) for clade C infection (cut-off q < 0.2). The entropy of beneficial and non-beneficial clade B OLP is
compared in C) while in D), the entropy of beneficial OLP in HIV clade C Gag is compared to the remainder of Gag OLP (p-values based on
Mann Whitney, red lines indicating median sequence entropies). In E and F, protein structures for HIV-1 reverse transcriptase (Protein databank
structure ID 3IG1) were loaded into the Los Alamos HIV Database “protein feature accent” tool http://www.hiv.lanl.gov/content/sequence/
PROTVIS/html/protvis.html and locations of beneficial RT OLP identified in clade B (Table 1) and in clade C (Table 2) marked by red highlights.
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Page 7 of 202E and 2F). This suggests that despite differences in
response patterns between ethnicities and clades, viruses
from both clades may be vulnerable to responses target-
ing the same structural regions of at least some of their
viral proteins.
Increased breadth of responses against beneficial OLP is
associated with decreasing viral loads, independent of
Gag-specificity or the presence of protective HLA class I
alleles
To assess whether individuals targeting more than one
beneficial OLP profit from a greater breadth of
responses to these targets, subjects in both cohorts were
stratified by the number of responses to beneficial OLP
and their viral loads compared. In both cohorts, negative
correlations between the number of responses to benefi-
cial OLP and viral loads were observed (p < 0.0001, r =
-0.33 for Lima; p < 0.0001, r = 0.-25 for Durban; data
not shown), suggesting that there is a cumulative benefit
of responses to these particularly effective targets. Simi-
larly, when individuals in the clade C cohort were
grouped based on mounting 1-2, 3-4 or five and more
beneficial OLP responses, a gradual reduction in median
viral loads was seen. This reduction was close to 20-fold
when 5 or more of the 22 beneficial OLP were targeted
(median viral load 5,210 copies/ml) compared to indivi-
duals without a response (98,800 copies/ml, Figure 3A).
Importantly, this observation was not driven only by
individuals expressing HLA class I alleles associated
with relative control of viral replication (including HLA-
Table 2 Beneficial and non-beneficial OLP identified in Durban clade C cohort (q < 0.2)
OLP # Protein Sub-unit OLP clade C
consensus
sequence
Median viral
load in OLP
responders
Median viral
load in OLP
non-responders
Protective Ratio
(PR)*
p-value Q-value
3 Gag p17 EKIRLRPGGKKHYMLKHL 18,700 45,100 1.09 0.0002 0.0006
6 Gag p17 ASRELERFALNPGLL 6,570 44,100 1.22 0.0000 0.0000
7 Gag p17 ERFALNPGLLETSEGCK 5,270 43,900 1.25 0.0000 0.0000
22 Gag p24 WVKVIEEKAFSPEVIPMF 8,360 42,850 1.18 0.0000 0.0000
25 Gag p24 GATPQDLNTMLNTVGGH 24,450 45,200 1.06 0.0021 0.0263
26 Gag p24 NTMLNTVGGHQAAMQMLK 5,310 39,600 1.23 0.0061 0.0766
27 Gag p24 GGHQAAMQMLKDTINEEA 9,715 42,100 1.16 0.0015 0.0170
29 Gag p24 AAEWDRLHPVHAGPIA 19,700 40,900 1.07 0.0045 0.0544
31 Gag p24 IAPGQMREPRGSDIA 6,480 38,950 1.20 0.0146 0.1478
33 Gag p24 SDIAGTTSTLQEQIAWM 11,650 40,900 1.13 0.0025 0.0318
37 Gag p24 WIILGLNKIVRMYSPVSI 9,360 44,100 1.17 0.0004 0.0018
39 Gag p24 SILDIKQGPKEPFRDYV 2,630 38,250 1.34 0.0182 0.1838
41 Gag p24 YVDRFFKTLRAEQATQDV 22,150 44,100 1.07 0.0020 0.0263
42 Gag p24 LRAEQATQDVKNWMTDTL 16,480 40,900 1.09 0.0078 0.0935
55 Gag p15 HIARNCRAPRKKGCWK 7,550 39,700 1.19 0.0092 0.1047
59 Gag p15 RQANFLGKIWPSHKGR 9,840 42,200 1.16 0.0046 0.0539
60 Gag p15 GKIWPSHKGRPGNFLQSR 6,130 39,700 1.21 0.0066 0.0799
63 Gag p15 TAPPAESFRFEETTPAPK 6,040 38,950 1.21 0.0093 0.1020
116 Tat Tat TKGLGISYGRKKRRQRRS 109,000 36,700 0.91 0.0033 0.0410
178 Pol RT FWEVQLGIPHPAGLKKKK 258,000 37,300 0.84 0.0033 0.0384
181 Pol RT LDVGDAYFSVPLDEDFRK 7,100 38,950 1.19 0.0186 0.1832
190 Pol RT RAQNPEIVIYQYMDDLYV 84,900 34,700 0.92 0.0043 0.0555
199 Pol RT TVQPIQLPEKDSWTVNDI 6,700 38,300 1.20 0.0198 0.1926
216 Pol RT QKIAMESIVIWGKTPKFR 18,150 43,000 1.09 0.0026 0.0317
239 Pol RT QVDKLVSSGIRKVLFL 373,200 37,700 0.82 0.0205 0.1937
253 Pol Int PAETGQETAYFILKLAGR 92,800 35,400 0.92 0.0082 0.0954
265 Pol Int AVFIHNFKRKGGIGGYSA 63,650 33,800 0.94 0.0178 0.1826
283 Vpr - GLGQYIYETYGDTWTGV 78,000 35,600 0.93 0.0126 0.1302
284 Vpr - ETYGDTWTGVEALIRIL 85,050 35,200 0.92 0.0099 0.1034
312 Env Gp120 YALFYRLDIVPLNENNSSEY 270,000 37,700 0.84 0.0208 0.1915
365 Env Gp41 GIKQLQTRVLAIERYLK 151,000 34,700 0.88 0.0001 0.0002
393 Env Gp41 LLGRSSLRGLQRGWEALKYL 750,000 37,450 0.78 0.0007 0.0041
417 Vif - CFADSAIRKAILGHIV 1,110 38,200 1.50 0.0178 0.1891
* PR values in bold indicate PR > 1, i.e. OLP-responses seen more frequently in individuals with reduced viral loads
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Figure 3 Increased breadth of responses to beneficial OLP results in gradually reduced viral loads and is independent of cohort and
HLA-B27, -57, -B58, -B81 and -B63.( A) The number of responses to beneficial OLP in the clade C cohort in Durban was determined for each
individual and compared to viral loads. An increased breadth of responses to the 22 beneficial OLP was associated with reduced viral loads
(ANOVA, p < 0.0001). (B) This association remained equally stable after removing all individuals expressing known beneficial HLA allele (HLA-B27,
-B57, -B5801, -B63, -B81) from the analysis (ANOVA, p < 0.0001). (C) The set of 26 beneficial and 17 non-beneficial OLP identified in the clade B
infected cohort in Lima, Peru was tested in a second clade B infected cohort in Barcelona. HIV controllers showed a significantly higher focus of
responses on the 22 beneficial OLP (61% of all responses to the 43 OLP) while non-controllers reacted predominantly with the non-beneficial
OLP (only 29% of all responses targeting beneficial OLP). The Barcelona cohort did not included subject expressing any HLA allele previously
associated with relative control of HIV-1 (p = 0.0011, Mann Whitney).
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Page 9 of 20B27, -B57, -B*5801, -B63 and -B81) as their exclusion
still showed a strong association between increased
breadth of responses to beneficial OLP and a gradual
suppression of viremia (Figure 3B). This was further
supported when translating the clade B data from Peru
to a second clade B infected cohort in Barcelona, Spain
where HIV-1 controllers also mounted a significantly
greater proportion of their responses to the beneficial
Peruvian OLP compared to the HIV-1 non-controllers
(61% vs. 29%, p = 0.0011; Figure 3C); this despite the
fact that the Barcelona cohort was genetically different
and excluded individuals expressing HLA-B27, -B57,
-B58 and B63. Thus, despite the frequent targeting of
Gag and the inclusion of individuals expressing HLA
alleles such as HLA-B*5701 and -B*5801 in the two lar-
g e rc l a d eBa n dCc o h o r t s ,t h ep r e s e n td a t ai d e n t i f y
regions of the viral genome that serve as the targets of
an effective host T cell response, largely independent of
the presence of HLA alleles known to influence HIV-1
viral replication.
PR-values are mediated by individuals with broad HLA
heterogeneity
To further assess the contribution of specific HLA class
I alleles on the PR of individual OLP, the statistically
significant OLP in the clade C cohort were further ana-
lyzed. In a first step, median viral loads in the OLP-
responder and non-responder groups were compared
after excluding individuals with specific HLA class I
alleles. If the statistical significance of the comparison
was lost, the excluded HLA class I allele was assumed
to have significantly contributed to the initially observed
elevated or reduced PR value and to restrict a potential
CTL epitope in that OLP. In a second step, a “Hepitope”
analyses http://www.hiv.lanl.gov/content/immunology/
hepitopes was conducted to identify HLA class I alleles
overrepresented in the OLP responder group; providing
an alternative approach to identify specific epitopes that
may contribute to relative viral control. Together, the
two strategies permit to estimate the HLA diversity in
the OLP responders and to identify the most likely
alleles that restrict the epitope-specific responses to the
OLP. Both are important measures when determining
the relative usefulness of a selected beneficial OLP in a
potential immunogen sequence as it should provide
broad HLA coverage. The data from these analyses are
summarized for beneficial and non-beneficial OLP in
Table 3 and 3, respectively. The results demonstrate
that with a few exceptions, for each OLP, several HLA
alleles appeared to be mediating the observed effects as
their removal caused the statistical significance to be
lost. However, for the most frequent HLA class I alleles,
the loss of significance may be due to a reduction in
sample size rather than the actual allele, since the
exclusion of many allele carriers could reduce the num-
ber of OLP responders (and non-responders) sufficiently
to lose statistical power. The “Hepitope” analysis con-
trolled for this effect and confirmed the obtained results,
strongly indicating that responses to beneficial OLP
were mediated by responder populations with heteroge-
neous HLA allele distributions.
Effects of T cell specificity on in vivo viral load are at
least as strong as those associated with host HLA
genetics
To assess whether specific response patterns and/or
HLA combinations could be identified that mediated
synergistic or superior control of viral infection in clades
B and C, multivariate combined regression analysis was
conducted on either OLP only, HLA only or the combi-
nation of OLP and HLA variables [41-43]. The OLP-
only analysis for Lima identified 7 OLP of which 4 were
associated with lower median viral loads and 3 with
increases in viral loads, respectively (Table 4). Targeting
at least one of these beneficial clade B OLP was asso-
ciated with significantly reduced viral loads (median 11,
079 copies/ml) compared to the subjects who did not
target any of these four OLP (median 52, 178 copies/ml;
p < 0.0001, Figure 4A). As seen in the univariate analy-
sis (Figure 2C), the four beneficial OLP emerging from
the Lima FASS analysis were more conserved than the
rest of the OLP (median entropy 0.0759 vs. 0.1649, p =
0.0267) or the three non-beneficial OLP (0.0759 vs.
0.1228, p = 0.0571, data not shown). In contrast to
OLP-only FASS analysis, only one HLA allele (HLA-
C04) emerged from the HLA-only multivariate analysis.
The analysis for the combined variables (OLP and HLA)
controlled for the potential bias in this result due to
more OLP variables (n = 389) than HLA (n = 146)
being included in the statistical tests; yet still identified
more OLP variables (n = 9) than HLA class I alleles (n
= 3). In addition, the relative co-efficients of these asso-
ciations were stronger for the OLP than the HLA vari-
ables, suggesting that T cell specificity influenced viral
loads to at least the same degree as host HLA class I
genetics. Of note, the identified OLP and HLA variables
did not reflect responses to known optimal CTL epi-
topes, as none of the OLP contained described epitope
(s) restricted by any of the identified HLA alleles [44].
Results from the clade C cohort in Durban confirmed
the clade B findings in Lima as the FASS analyses iden-
tified 16 OLP but only 8 HLA variables that had an
impact on the individual viral loads. As in Lima, the
impact of OLP specificity was at least as strong than
HLA genotype (trend for higher coefficients for OLP
than HLA; data not shown, p > 0.05). In addition, tar-
geting at least one of the eight beneficial OLP in Durban
was associated with strongly reduced viral loads (p <
Mothe et al. Journal of Translational Medicine 2011, 9:208
http://www.translational-medicine.com/content/9/1/208
Page 10 of 20Table 3 Impact of HLA alleles on the statistical significance of observed PR values (clade C OLP)
A) Beneficial OLP (PR > 1)
OLP Protein PR Removed HLA allele(s) abolishing statistical
significance
1
Alleles over-represented in the OLP
responder group
2
3 Gag 1.09 A30, B42, C17 A30, B08, A03, A74, C17, A43, B42, B07
6 Gag 1.22 B15 B49, B82, C14
7 Gag 1.25 - B42, C17, B49, A30
22 Gag 1.18 B57, C07 B57, A74, B45, C07, C16, B13
25 Gag 1.06 A30, B15, C04, C07 B42, C17, B81, B39, A01, C12, C18, A30, B67
26 Gag 1.23 A02, A23, A68, B07, B14, B58, C07, C08 C03, B15, A68
27 Gag 1.16 B15, C07 B15, A68, C03, C08
29 Gag 1.07 A68, B15, B58, C02, C03, C06, C12 B35, B39, C12, B40, B07, C04
31 Gag 1.2 A02, A11, A23, A29, A32, A34, A68, B07, B13, A29, C06, A11
B13, B15, B42, B44, B58, C04, C06, C07, C17
33 Gag 1.13 A02, A23, B44, B57, B58, C07 B58, B57, A02, C07, C03, A68
37 Gag 1.17 A30, B42, B58, C17 C18, B42, C17, A01, B81
39 Gag 1.34 A02, A03, A23, A29, A30, A68, A74, B08, B15, A02
B18, B42, B45, B53, B57, B58, C02, C03, C06,
C07, C08, C16, C17
41 Gag 1.07 A23, C06 C03, B14, A68, C08, B15
42 Gag 1.09 A23, A30, B08, B15, B42, B53, B58, C03, C04, C07 B53, C03
55 Gag 1.19 A02, A24, A29, A30, B07, B15, B39, B42, B44, B42, B08, C17
B58, C02, C06, C07, C17
59 Gag 1.16 A02, A30, B08, B42, B44, B58, C04, C07, C17 A02, B13, A29
60 Gag 1.21 A02, A30, B42, B58, C06, C07, C17 A02, B41, C07, C17
63 Gag 1.21 A02, A23, A29, A30, A68, B08, B15, B44, B58, A23
C02, C03, C06, C07
181 Pol 1.19 A01, A23, A29, A30, A34, A68, A74, B14, B15, B57, C18
B18, B35, B44, B45, B57, B58, C02, C03, C04,
C06, C07, C08, C16
199 Pol 1.2 A02, A03, A23, A24, A26, A30, A31, A34, A36, A66, A68, B53, A23, C04
A80, B08, B13, B15, B18, B35, B40, B41, B42, B44, B45,
B49, B50, B51, B53, B57, B58, B81, C01, C02, C03,
C04,
C05, C06, C07, C08, C15, C16, C17
216 Pol 1.09 A02, A30, B58, C07, C17 B53, B58, C07, B57
417 Vif 1.5 A03, A23, A30, A34, A36, A68, B08, B14, B15, B14, C08, A36
B44, B53, B58, C03, C04, C06, C08
B) Non-beneficial OLP (PR
<1 )
116 Tat 0.91 A02, A34, B15, C04 B15, C02
178 Pol 0.84 A03, A68, B15, B58, C04, C06, C07 A68, C06, B58, B82, A03
190 Pol 0.92 A03, A30, A66, B18, B42, B45, B58, C06, C07 A02, B18, B35, C05, C16, B45, A80, C12, B67, B39
239 Pol 0.82 - C05, A03
253 Pol 0.92 A03, A68, B15, B39, B42, B44, B58, C02, C04, C06, C08, A68, C03, B15, B07, C15, B41
C17, C18
265 Pol 0.94 A02, A03, A23, A24, A26, A29, A30, A31, A33, B15, C02, A43, A74
A34, A66, A68, B07, B08, B14, B15, B27, B40, B41, B42,
B44, B53, B54, B55, B57, B81, C01, C02, C04, C06, C07,
C12, C17, C18
283 Vpr 0.93 A02, A03, A23, A30, A66, A68, A74, B07, B14, B18, B39, A68, C03, B07, C17, B41
B41, B42, B45, B57, C02, C04, C07, C08, C15, C17
284 Vpr 0.92 A03, A23, A30, A66, A68, A74, B07, B14, B18, B39, B42, A68, C03
B45, B57, C07, C08, C15, C17
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Page 11 of 200.0001, Figure 4B). This effect was, as in the univariate
analysis, additive for more than one response (p <
0.0001, Figure 4C) and included OLP that were, aside
from Gag, located in Pol and Vif. Also, the combined
(OLP and HLA) analysis suggests the effect of OLP spe-
cificity on viral loads to be at least as strong as HLA
genetics as 8 OLP and 7 HLA variables were identified.
This especially since among the 7 HLA alleles, two
(HLA-B57 and HLA-A74) are expressed in linkage dise-
quilibrium [47], further reducing the number of HLA
variables with a significant impact on viral loads.
Responses to beneficial OLP are of higher functional
avidity and suppress viral replication in vitro more
effective than responses to non-beneficial OLP
Functional avidity and the ability to suppress in vitro
viral replication have emerged as two potentially crucial
parameters of an effective CTL response against HIV-1
[23-29]. To assess this potential functional characteristic
of beneficial CTL populations, we determined the func-
tional avidity of responses to the four beneficial OLP
located in Gag p24, a region that has been most consis-
tently associated with eliciting relatively protective CTL
responses. As 18 mer peptides are suboptimal test pep-
tides to determine functional avidity, 10 mer overlapping
peptide sets were synthesized to cover the four benefi-
cial OLP and all detected responses were titrated. The
SD50% was determined for a comparable numbers of
responses detected in controllers (n = 21 responses) and
non-controllers (n = 24 responses) and showed a statis-
tically significant difference between the two groups
(median 3, 448 ng/ml vs. 25, 924 ng/ml, p = 0.0051, Fig-
ure 5A). This reduced avidity in HIV non-controllers to
beneficial OLP could possibly explain why HIV-1 non-
controllers did not control their in vivo viral replication
despite targeting these regions in some instances and
with responses of comparable magnitude as HIV con-
trollers (278 SFC vs 305 SFC/10
6 PBMC, p = 0.55, data
not shown).
To more directly assess whether responses to benefi-
cial OLP were of particularly high functional avidity,
regardless of HIV controller status, we determined
SD50% of responses to 17 optimal epitopes from benefi-
cial, neutral and non-beneficial OLP (Figure 5B). Med-
ian epitope-specific SD50% were determined from an
average of 7 titrations per epitope and compared to the
OLP specific PR. A strongly significant, negative associa-
tion between the PR and the SD50% was noted (p =
0.002, r = -0.69), indicating that beneficial OLP are tar-
geted by high-avidity respon s e s .T oc o n t r o lf o ri n t e r -
individual differences due to disease status and viral
load, we identified 10 individuals who targeted optimal
epitopes in beneficial and non-beneficial OLP and deter-
mined their functional avidity. As in the cross-sectional
analysis before, this matched comparisons showed in all
cases a higher functional avidity for the epitopes located
in the beneficial OLP compared to the responses target-
ing non-beneficial OLP (Figure 5C, p = 0.0020). Lastly,
to relate the higher functional avidity to potential super-
ior anti-viral effects in vivo, the ability to inhibit in vitro
viral replication was assessed in three individuals who
mounted robust responses against both beneficial and
non-beneficial OLP. The in vitro inhibition assay first
developed by Yang et al [48], was modified so that the
NL4-3 based test virus contained a single nucleotide
mutation in Nef (M20A) that blocks the Nef-mediated
down-regulation of HLA class I molecules as well as
two mutations in the integrase gene that mediate Ralte-
gravir-resistance to permit the suppression of potentially
replicating autologous virus in the assay. Indeed, CTL
specific for the beneficial OLP(s) were up to 2 logs
more effective inhibiting viral replication than CTL tar-
geting non-beneficial OLP (Figure 5D), in line with
recent data demonstrating different suppressive ability
of HIV-1 specific CTL populations targeting Gag and
Env-derived epitopes [24]. Although the in vitro inhibi-
tion assays were limited to few individuals with suitable
response patterns, these data together with the results
from the extensive titration assays in Figure 5B and 5C
indicate that responses to beneficial OLP are of particu-
larly high functional avidity and inhibit in vitro viral
replication more effectively than responses to non-bene-
ficial OLP. Of note, higher avidity responses to benefi-
cial OLP compared to non-beneficial OLP were seen in
all 10 tested individuals, ruling out that inter-individual
variability in viral loads, duration of infection and HIV
disease status could have biased the analyses.
Conclusions
Defining functional correlates of HIV-1 immune control
is critical to the design of effective immunogens. T cell
responses to specific HIV-1 proteins and protein-
Table 3 Impact of HLA alleles on the statistical significance of observed PR values (clade C OLP) (Continued)
312 Env 0.84 - B08, C07
365 Env 0.88 B58, C06 C06, B58, A43, B45, C16, A66
393 Env 0.78 A30, B58, C06 A31, C06, B45
1) in italics HLA alleles that do not emerge from the Hepitope analysis 2) cut-off in Hepitope analyses for p < 0.05, alleles sorted according to strengtho f
association
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Page 12 of 20Table 4 Multivariate analysis of OLP and HLA variables for clade B and C cohorts
OLP variables only (Lima, clade B) OLP variables only (Durban, clade C)
change viral load (co-efficient) * p-value change viral load (co-efficient) * p-value
Beneficial Beneficial
OLP.6 -0.4591 0.0008 OLP.7 -0.6256 0
OLP.31 -1.4055 0.0002 OLP.21 -0.6663 0
OLP.171 -2.5981 0 OLP.22 -0.4926 0.0006
OLP.276 -1.127 0.0007 OLP.25 -0.2822 0.0002
OLP.27 -0.4719 0.0053
Non-beneficial OLP.33 -0.3396 0.0024
OLP.76 0.2486 0.0067 OLP.398 -1.8179 0.0027
OLP.306 3.2968 0.0001 OLP.417 -1.6535 0.0008
OLP.411 1.3329 0.012
Non-beneficial
OLP.38 0.9045 0.0022
OLP.84 0.1947 0.0091
OLP.116 0.6156 0.0039
OLP.183 0.661 0.0013
OLP.224 0.2508 0.0036
OLP.265 0.5782 0
OLP.365 0.4911 0.0009
OLP.393 1.2624 0.0013
HLA variables only (Lima, clade B) HLA variables only (Durban, clade C)
Non-beneficial Beneficial
HLA-C0401 0.35652 0.00024 HLA-A74 -0.3553 0.0025
HLA-B13 -0.6443 0.0004
HLA-B57 -0.5195 0.0007
HLA-B81 -0.3619 0.0015
HLA-C12 -0.6544 0.0001
Non-beneficial
HLA.B.15 0.2506 0.0012
HLA.B.18 0.5521 0.0005
HLA.C.6 0.3958 0
HLA and OLP variables together (Lima) HLA and OLP variables together (Durban)
Beneficial Beneficial
OLP.6 -0.5792 0 OLP.6 -0.4798 0.0023
OLP.31 -1.1607 0.0005 OLP.7 -0.4528 0.0015
OLP.171 -2.7948 0 OLP.27 -0.4676 0.0049
OLP.276 -0.9609 0.0011 OLP.59 -0.4196 0.0115
OLP.417 -1.387 0.0041
Non-beneficial Non-beneficial
OLP.2 0.3945 0.018 OLP.148 2.5215 0.0029
OLP.237 0.7211 0.0035 OLP.183 0.6108 0.0023
OLP.288 1.5537 0.0016 OLP.393 1.1442 0.0023
OLP.311 0.7197 0.0091
OLP.411 1.5306 0.0024 Beneficial
HLA-A74 -0.3744 0.0007
Beneficial HLA-B57 -0.4887 0.0007
HLA-B1502 -1.4688 0.0164 HLA-B81 -0.3859 0.0004
HLA-C12 -0.6003 0.0002
Non-beneficial Non-beneficial
HLA-B0801 0.66 0.0049 HLA-B15 0.2797 0.0001
HLA-C0401 0.2894 0.0006 HLA-B18 0.5316 0.0003
HLA-B49 0.9713 0.0007
* negative co-efficient values indicate reduction in median viral loads
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Figure 4 Responses to OLP identified in multi-variate analysis are associated with reduced viral loads: Response patterns and HLA class I
genetics in the clade B cohort in Lima and clade C cohort in Durban were subjected to FASS multivariat analysis [41-43]. Viral loads in
individuals mounting zero vs. at least one response to beneficial OLP identified by the FASS multi-variate analysis were compared for (A) the
Lima clade B cohort and the (B) Durban clade C cohort. The larger data set for the clade C cohort allowed for a further stratification of the
responder group by increasing numbers of targeted OLP emerging from the FASS analysis (C). A gradually declining median viral load in relation
to an increasing breadth of these responses was seen (ANOVA, p < 0.0001).
Mothe et al. Journal of Translational Medicine 2011, 9:208
http://www.translational-medicine.com/content/9/1/208
Page 14 of 20subunits have been associated before with relatively
superior viral control in vivo [14,16,49], but evidence
from recent clinical trials suggests that including maxi-
mal immunogen content into various vectors does not
necessarily induce more effective CTL responses [50,51].
In fact, it has been argued that the existence of potential
“decoy” epitopes may divert an effective CTL response
towards variable and possibly less effective targets in the
viral genome [52]. Thus, the definition of a minimal yet
sufficient immunogen sequence that can elicit CTL
responses in a broad HLA context is urgently needed.
Thereby, focusing vaccine responses on conserved
regions could help induce responses towards mutation-
ally constrained targets and provide the basis for protec-
tion from heterologous viral challenge.
We present here the results of an extensive analysis
that included more than 950 HIV-1 infected individuals
with diverse HLA genotypes, from three different conti-
nents and including clade B and C infections. In both,
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Figure 5 Responses to beneficial OLP are of higher functional avidity and suppress in vitro viral replication more effectively.( A)
Responses to the four beneficial OLP located in HIV-1 clade B Gag p24 were retested using a peptide set of 10 mers overlapping by 9 residues.
A total of 21 responses in HIV-1 controllers and 24 responses in HIV-1 non-controllers were titrated and the SD50% compared between the two
groups, showing a significantly higher functional avidity in the controllers (p = 0.0051, Mann Whitney). (B) Responses to 17 different optimally
defined CTL epitopes located in beneficial, neutral and non-beneficial OLP were titrated in samples from 78 HIV infected individuals with variable
viral load and disease status. The median SD50% (ng/ml) was defined for each epitope and compared to the OLP-specific protective ratio
(Spearman Rank test, p = 0.0020). (C) Ten individuals who mounted responses to well-defined optimal CTL epitopes located in beneficial as well
as in non-beneficial clade B OLP were identified and their responses titrated. The SD50% for responses detected in the same individual were
compared (Wilcoxon matched pairs test, p = 0.0039). (D) In-vitro viral replication inhibition assays [48] were performed using a Nef modified and
Raltegravir resistant test virus and purified CTL effector populations from the same individual targeting beneficial and non-beneficial OLP. One
representative experiment of three assays conducted in different individuals is show. Levels of Gag p24 were determined after 4 days of co-
culture of effector cells and auologous CD4 T cells used as target cells. Target cells were stimulated 3 days prior with dual-specific anti-CD3/8
mAb and infected at a MOI of 0.1. The negative control contained wells with target cells only ("no CD8”).
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Page 15 of 20individual OLP were identified that are predominantly
targeted by individuals with reduced or elevated viral
loads, although the different size of the cohorts required
different statistical approaches for their identification. In
general, most of these OLP were among the more fre-
quent targets in the HIV proteome, possibly due to
both, the need for sizable responder groups to achieve
statistical significance in the viral loads comparison as
well as the high epitope density in these OLP. The iden-
tified OLP were frequently located in HIV-1 Gag and
Pol, but rarely in the more variable proteins such as Env
and Nef. With one exception, Nef and Env featured only
non-beneficial OLP, thus arguing against their inclusion,
at least as full proteins, in a CTL immunogen sequence
[16]. In addition, in both cohorts, the Vif protein yielded
few, yet exclusively beneficial OLP, which may warrant a
renewed look at the inclusion of regulatory proteins in
vaccine design [53,54]. Also common to both clades,
(and despite the wide scatter possibly due to the inclu-
sion of less-frequently targeted OLP), an negative corre-
lation between sequence entropy and PR was observed
providing strong rationale for vaccine approaches that
focus on conserved viral regions where T cell escape
may be complicated by structural constrains [55]. This
was particularly evident in the clade C cohort, where
even within the relatively conserved Gag protein, a
lower entropy was seen for the beneficial OLP compared
to the remainder of the OLP spanning the protein. On
the other hand, while beneficial and non-beneficial OLP
showed a significant difference in their median entropy
in the clade B cohort, this comparison was not signifi-
cant in the clade C cohort. It is possible that the immu-
nogen sequence, designed in 2001, did not optimally
cover the circulating viral population in Durban
throughout the enrollment period (until 2006), leading
to missed responses particularly in the more variable
segments of the virus [32,56]. The study may have thus
failed to identify beneficial as well as non-beneficial
OLP in the more variable genes of HIV. This should
have preferentially affected highly variable OLP due to a
more frequent mismatch between autologous viral
sequence and in vitro test set in these regions. However,
even if scoring as beneficial OLP, such high-entropy
OLP may from an immunogen-design point of view be
of less interest as they would possible contribute only
little to protection from heterologous viral challenge. It
needs however also to be considered that the OLP-spe-
cific entropy values are based on variable numbers of
sequences in the Los Alamos HIV database covering the
different OLP, introducing potential further bias into
these analyses, particularly for less covered proteins
such as Vpu and other viral protein products. Such dif-
ferences between autologous viral sequences and in
vitro test sets may also have impacted the assessment of
functional avidities. These determinations included
responses in the same individual towards epitopes
located in beneficial and non-beneficial OLP; with the
former overall being more conserved. Thus, the higher
functional avidity towards epitopes located in beneficial
OLP could be biased by the higher chance that these
epitopes matched the autologous viral sequence com-
pared to epitopes located in non-beneficial OLP and
which may thus have induced a more robust, avid
response. Apart from covering autologous sequences,
future studies will ideally also include comparable ana-
lyses in individuals identified and tested in acute infec-
tion that go on to control the infection at undetectable
levels of viral replication (i.e. elite-controllers) so that
the selective early emergence of responses to beneficial
OLP could be linked to relative control of viral replica-
tion in chronic infection. As is, the identified beneficial
responses may be particularly important to maintain low
viral replication in chronic stages of infection, which in
theory could be different (for instance due to more
accelerated intra-individual viral evolution in variable
genes) from responses determining viral set point during
acute infection. However, the existing HLA bias in such
cohorts and the small number of responses identified
during earliest stages of infection may make such ana-
lyses a formidable undertaking that will require large
numbers of individuals to be tested longitudinally.
A broadly applicable T cell immunogen sequence
should include T cell targets restricted by a wide array
of HLA class I alleles. Although broad representation of
HLA-B alleles may be particularly important in this
regard, emerging data on the effects HLA-C alleles in
these cohorts may warrant a broad HLA-C representa-
tion as well [2,47,57]. In the present study, the 26 bene-
ficial OLP from Lima and the 22 beneficial OLP from
Durban covered 26 described, optimally defined CTL
epitopes restricted by 20 different HLA alleles for the
clade B cohort and 33 epitopes presented by 34 alleles
for the clade C cohort, respectively [44]. As this is likely
to be an underestimate of the true diversity in HLA
restriction (Table 2 and ref [58]), it is reasonable to pre-
dict that the inclusion of identified beneficial OLP, or
even a subset thereof, could evoke potential responses
in a widely diverse HLA context. This could also pro-
vide the basis for the induction of poly-specific T cell
responses with increased breath, which the present data
clearly associates with progressively lower viral loads
and which emerge as a potentially important parameter
from several recent vaccine studies showing superior
protection from SIV challenge in animals with a broad
vaccine induced responses to Gag p17 [59,60].
Recent studies have suggested a global adaptation of
HIV-1 to its various host ethnicities [4,46]. The conse-
quence of such adaptation has led in some cases to the
Mothe et al. Journal of Translational Medicine 2011, 9:208
http://www.translational-medicine.com/content/9/1/208
Page 16 of 20elimination of protective CTL targets, causing a pro-
found absence of responses to these epitopes and detri-
mentally changing the association between HLA allele
and HIV-1 disease outcome [4]. It is thus not surprising
that the two main cohorts tested here yielded only par-
tially overlapping sets of beneficial OLP as the impact of
host genetics and viral evolution in the studied popula-
tions cannot readily be overcome. In fact, given studies
by Frahm et al [4], the past and current adaptation of
HIV-1 to common HLA class I alleles will likely still call
for somewhat population tailored vaccine approaches,
especially if the immunogen sequences should be kept
short to avoid regions of potentially reduced immunolo-
gical value [52]. Such approaches will also profit from
more extensive structural analyses that may identify spe-
cific domains of viral proteins that are or are not
enriched in valuable T cell targets; of which the latter
could possibly be ignored for the design of T cell immu-
nogen sequences. Additional analyses in other geneti-
cally unrelated cohorts of HIV-1 infected individuals
and studies in SIV infection may further help to guide
such selective immunogen design and to understand the
factors defining the effectiveness of different epitopes in
mediating relative HIV-1 control. Of note, the beneficial
OLP identified here, 24 in clade B and 22 in clade C
infection matched other immunogen design based on
conserved elements in some parts as well, i.e. of the 14
conserved elements proposed by Hanke et al, eight
(57%) overlapped at least partly with beneficial OLP
identified here [61]. Similarly, among the highly con-
served elements proposed by Rolland et al [52], 35% (5/
14) were covered by our beneficial OLP in clade B infec-
tion. These differences possibly emerge because the pre-
sent analysis is based on functional T cell data rather
than viral sequence alignments, which may not take into
consideration epitope density and processing preferences
of certain regions. Nevertheless, the partial overlap with
these other immunogen design support the focus on
conserved regions and offers the opportunity for alterna-
tive or combined vaccine approach that elicit responses
to regions where the virus is and possibly remains vul-
nerable [4,46,55,62].
Finally, we used the extensive data set available to
approach the question of relative effects of host genetics
(i.e. HLA) and CTL specificity on HIV-1 control. While
the two factors cannot be entirely disentangled, our data
suggest that CTL specificity has an at least equal if not
stronger effect on viral control than HLA class I allele
expression. These findings are also in line with data by
Mothe et al [63] showing that targeting key regions in
p24 surrounding the dominant epitopes restricted by
known protective alleles (KK10 for HLA-B27 and TW10
for HLA-B57/58) in HLA-B27, -57 or B58 negative indi-
viduals is associated with significantly reduced viral
loads. In addition, the presence of individuals not
expressing known beneficial alleles in HIV-1 elite con-
troller cohorts [64], further indicates that HIV-1 control
is not necessarily bound to a few specific HLA class I
alleles. A detailed study of the total HIV-1-specific CTL
response of subjects not expressing these alleles yet
effectively controlling HIV-1 can be expected to provide
further and crucially needed insight into the importance
of targeting specific (conserved) regions of the viral gen-
ome for HIV-1 control. Similarly, the characterization of
functional attributes of these responses, including func-
tional avidity and the ability to suppress in vitro viral
replication will need to be further assessed in such indi-
viduals. Building on experimentally derived and poten-
tially promising immunogen sequences as defined here
may thus provide a suitable basis for further immuno-
gen design and iterative clinical trials in the human
setting.
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